CHITA – a registry of in vitro NAMs
Researchers are using phenotypic assays at earlier and earlier stages of drug discovery. Assays for use in hit triage must be exceptional. In a previous post we’ve described the impact…
Quietly happening beneath the radar, phenotypic platforms are becoming integrated into drug discovery processes. Why this is happening and how are phenotypic assays transforming the stages of drug discovery? Multiple…
A strong chain of translatability is crucial for successful drug discovery programs. The chain of translatability is a molecular-level association between the mechanisms that drive the assay phenotype, the preclinical disease…
VCAM-1 is one of our favorite biomarkers. The levels of this clinical biomarker are increased in patients with diseases as diverse as Parkinson’s disease and arthritis. The regulation of VCAM-1…
It’s not just about measuring what matters – it’s about making what you measure matter. There are many options for endpoints to measure in phenotypic assays. Endpoints to consider include…
Developing phenotypic assays that model human disease is a heavy lift. Our understanding of disease biology is limited. And there are so many variables, it’s hard to know where to…
How do we design phenotypic assays that are physiologically relevant? And what do we mean by “relevant”? For those of us working in drug discovery or chemical safety, what we…
When I started out in tissue culture of primary human cells, there were few methods available and few options for cell types. Most human cell-based assays used immortalized cell lines…
Phenotypic assays using human cell types can help replace animal testing in drug discovery and product development. We can’t trust these assays, however, if we can’t explain why or why…
In drug discovery and chemical safety research, validation lies at the heart of every assay, reagent and experiment. Validation is fundamental for life sciences research effectiveness and, according to Scannell and…
